Paradigm, a molecular information and next-generation sequencing (NGS) corporation specializing in cancer testing, has signed an agreement with health insurer Three Rivers Provider Network Inc., one of the nation’s largest and fastest-growing preferred provider networks.
Under the terms of the agreement, Paradigm's Cancer Diagnostic Test (PCDx) will become available to more than 15 million U.S. members of Three Rivers Provider Network.
Paradigm brings cutting-edge diagnostics to cancer patients and industry by providing information about the genomic makeup of the patient's cancer and potential therapies. Its diagnostic test is driven by supporting data and literature and provides more choices for patient care than are currently available on the market.
PCDx is an NGS-based diagnostic test designed to provide physicians and patients with information allowing a more targeted, personalized approach to cancer treatment by identifying the underlying genomic and proteomic alterations of a tumor's DNA, RNA and protein.
"We continue to make strong progress with provider networks to ensure our best-in-class NGS test is available to the millions of Americans who are suffering with cancer,” Paradigm CEO Robert Penny said. “With this contract, millions of patients and their treating clinicians will have access to our leading oncology testing service and make possible more informed and individually tailored treatment strategies."
Three Rivers Provider Network was established in 1996 and is now comprised of more than 550,000 total providers, including more than 5,000 hospitals and 70,000 ancillary facilities.